Recovery of microcirculation after intracoronary infusion of bone marrow mononuclear cells or peripheral blood mononuclear cells in patients treated by primary percutaneous coronary intervention: The Doppler substudy of the Hebe trial

Anja M. Van Der Laan, Alexander Hirsch, Joost D.E. Haeck, Robin Nijveldt, Ronak Delewi, Bart J. Biemond, Jan G.P. Tijssen, Koen M.J. Marques, Felix Zijlstra, Albert C. Van Rossum, Jan J. Piek*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

8 Citations (Scopus)

Abstract

Objectives: In the present substudy of the Hebe trial, we investigated the effect of intracoronary bone marrow mononuclear cell (BMMC) and peripheral blood mononuclear cell (PBMC) therapy on the recovery of microcirculation in patients with reperfused ST-segment elevation myocardial infarction (STEMI). Background: Several studies have suggested that cell therapy enhances neovascularization after STEMI. Methods: Paired Doppler flow measurements were available for 23 patients in the BMMC group, 18 in the PBMC group, and 19 in the control group. Coronary flow was assessed at 3 to 8 days after primary percutaneous coronary intervention (PCI) and repeated at 4-month follow-up, with intracoronary Doppler flow measurements. Results: At baseline, the coronary flow velocity reserve was reduced in the infarct-related artery and improved over 4 months in all 3 groups. The increase of coronary flow velocity reserve did not significantly differ between the 2 treatment groups and the control group (BMMC group: 2.0 ± 0.5 to 3.1 ± 0.7; PBMC group: 2.2 ± 0.6 to 3.2 ± 0.8; control group: 2.0 ± 0.5 to 3.4 ± 0.9). Additionally, the decrease in hyperemic microvascular resistance index from baseline to 4-month follow-up was not statistically different between the 2 treatment groups and the control group. Conclusions: In STEMI patients treated with primary PCI in the Hebe trial, adjuvant therapy with BMMCs or PBMCs does not improve the recovery of microcirculation. Therefore, our data do not support the hypothesis of enhanced neovascularization after this mode of cell therapy. (Multicenter, randomised trial of intracoronary infusion of autologous mononuclear bone marrow cells or peripheral mononuclear blood cells after primary percutaneous coronary intervention [PCI]; ISRCTN95796863)

Original languageEnglish
Pages (from-to)913-920
Number of pages8
JournalJACC: Cardiovascular Interventions
Volume4
Issue number8
DOIs
Publication statusPublished - Aug 2011
Externally publishedYes

Bibliographical note

Funding Information:
The study is financially supported by funds provided by the Interuniversity Cardiology Institute of the Netherlands, Utrecht, the Netherlands; the Netherlands Heart Foundation (2005T101); and by unrestricted grants from Biotronik , Boston Scientific , Guerbet , Guidant , Medtronic , Novartis , Pfizer , and Sanofi-Aventis . Dr. van der Laan received a grant by the Graduate School for Medical Sciences of the Academic Medical Center, University of Amsterdam , Amsterdam, the Netherlands. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Fingerprint

Dive into the research topics of 'Recovery of microcirculation after intracoronary infusion of bone marrow mononuclear cells or peripheral blood mononuclear cells in patients treated by primary percutaneous coronary intervention: The Doppler substudy of the Hebe trial'. Together they form a unique fingerprint.

Cite this